secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001493152-24-028283
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma reports favorable Phase 1 SAD results for CDI-988 oral pan-viral protease inhibitor
--------------------------------------------------------------------------------

- CDI-988 showed favorable safety and tolerability in SAD cohorts; doses from 100 mg to 600 mg.
- No serious adverse events, severe TEAEs, or clinically significant lab/ECG findings; all 48 participants completed.
- CDI-988 targets a conserved 3CL protease region; potential first dual broad-spectrum treatment for norovirus and coronavirus.
- MAD cohort enrollment planned to start in Q4 2024; drug product currently being manufactured.
- Norovirus causes ~21M US cases/year; no approved antiviral or vaccine for norovirus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224028283/0001493152-24-028283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224028283/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer